ENEDYM-INC
10.5.2022 14:02:15 CEST | Business Wire | Press release
Enedym Inc. (“Enedym”), a technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, today announced a strategic partnership with Smartricity Inc. (“Smartricity”), a smart industrial electric motor and software company. The partnership will help deliver next generation wind pitch motors and related technology to materially increase efficiency, performance, and cost-effectiveness.
Utilizing Enedym’s unique SRM technology, Ventium – whose name is a combination of the Latin words for wind (Ventus) and power (Imperium) – increases the reliability and efficiency of wind turbines, which leads to an increase in energy production. Over time, increased wind energy production will displace fossil fuel electricity generation, resulting in significant reductions in greenhouse gas emissions. In addition, increased efficiency of wind turbines reduces the cost of wind energy, making investments in clean wind energy more attractive. Enedym and consortium partner Smartricity, were recently awarded $2.4 million by Sustainable Development Technology Canada (SDTC) to commercialize and advance the Ventium wind pitch motor technology.
As part of the collaboration, Enedym and Smartricity will work to maximize the contribution that wind energy can make by addressing a major weakness in turbines: low availability and capacity factor due to unreliable and outdated wind pitch drive systems in 1.X-2.X MW models. The pitch systems in the 1.X-2.X are one of the largest contributors to turbine downtime, with studies showing over 30% of failures directly related to these systems.
Dr. Ali Emadi, Founder, President, and CEO of Enedym said, “We are pleased to announce this agreement with Smartricity and jointly reach our goal to ensure wind power infrastructure can run more efficiently, reliably, and economically. Global appetite for clean energy is projected to accelerate dramatically, both to reduce reliance on foreign fossil fuel-based power generation and to ensure geo-political risks are reduced. We are eager to partner and work with Smartricity, industry leaders, and renewable energy companies to drive the innovation that will move us towards a greener and more secure future.”
Michael Sonsogno, Co-Founder and CEO of Smartricity, said, “Smartricity has built an arsenal of revolutionary motor technologies from around the world and paired it with our team’s expert application knowledge to address major weaknesses in the Renewables, HVAC, Mining, Oil and Gas, and Industrial Manufacturing industries. In the Wind Pitch application, SRM was the clear winner when combined with our real-world field insights to produce the Ventium Wind Pitch SRM.”
About Enedym Inc.
Enedym is a technology start-up company from McMaster University. The company is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 60 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair in Hybrid Powertrain Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. Enedym’s vision is to significantly reduce the cost of electric motors and electrified powertrains, and power a new paradigm in electrification through novel electric motor drive technologies, controls, and digitization techniques. Enedym aspires to help save the planet, one electric motor market at a time. To learn more about Enedym, please visit www.enedym.com and our YouTube channel at Enedym YouTube .
About Smartricity Inc.
Smartricity is a smart industrial electric motor and software company. Smartricity’s motors are created using disruptive electric motor technologies, software, and data analytics; Smartricity’s highly efficient, ultra-reliable, and sustainable motors will drastically increase critical asset uptime while greatly reducing emissions, waste, and massive industrial carbon footprint. To learn more about Smartricity and the Ventium Wind Pitch SRM please visit www.Smartricity.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005647/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom